TPP Global Development Ltd Enters into a Collaboration Agreement with Sprint Biosciences AB To Develop Small Molecule Inhibitors of Choline Kinase

EDINBURGH, Scotland--(BUSINESS WIRE)--TPP Global Development Ltd (TPP) enters into a collaboration with Sprint Bioscience AB to develop small molecule inhibitors of choline kinase as human therapeutics for the treatment of cancer.

“We are delighted to have entered into this agreement to work with Sprint Bioscience, and look forward to utilising their expertise in fragment-based drug discovery and development. Choline Kinase is an exciting metabolic target and fits well within the rest of TPP’s cancer metabolism portfolio.”

Under the terms of the agreement TPP and Sprint Bioscience will work together to further the development of small molecule inhibitors of choline kinase as human therapeutics for the treatment of cancer. Tom Brown, TPP’s CEO commented, “We are delighted to have entered into this agreement to work with Sprint Bioscience, and look forward to utilising their expertise in fragment-based drug discovery and development. Choline Kinase is an exciting metabolic target and fits well within the rest of TPP’s cancer metabolism portfolio.”

For more information please visit www.tppgd.com

Notes to Editors:

TPP Global Development

TPP is a UK-based, biotechnology company focused on developing preclinical drug development programmes around three main therapeutic areas: oncology, neuro-degeneration, immunology/inflammation. By combining proven drug development expertise with a sharp commercial focus, TPP is progressing a portfolio of novel chemical assets within the disease areas listed above. Globally, TPP has established an extensive network of collaborations with leading life science research institutes and other industry participants allowing it access to the most exciting, emerging therapeutic targets and pathways.

Sprint Biosciences AB

Sprint Bioscience is a Swedish company developing oncology therapeutics targeting cancer metabolism, founded by experienced drug developers with an ambition to improve the drug discovery process. The company has developed an efficient, fragment-based drug discovery (FBDD) platform that can take parallel projects from initial idea to active molecules tested in cell-based systems in a very short time.